Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do not respond well to EGFR-TKIs therapy

It’s essential to note our commitment to transparency:

Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. As a platform hosting over 100,000 pieces of content published daily, we cannot pre-vet content, but we strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation.